BioSpace News Archive

Manhattan Scientifics Inc. a company that acquires, develops and commercializes life-enhancing technologies is pleased to announce year-end business updates on its two nano technologies for 2020: its Nano-Medicine Cancer and Nano-Medical Metal Alloy ventures.

Brooklyn ImmunoTherapeutics LLC, a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, announced the initiation of an open-label Phase 2 clinical trial of IRX-2 in combination with pembrolizumab and chemotherapy in triple negative breast cancer.

A seasoned veteran of the prescription drug industry has broken ranks with the status quo and launched a new business to inject more transparency and competitiveness into how drugs are marketed and distributed in the United States.

Marks the First Pure Open Access Publisher to Implement CCC’s Market-Leading SaaS Platform for Institutional Agreement Management

Corteva AgriscienceTM has signed a multi-year agreement with Genestack Limited to implement and license the use of Omics Data Manager, Genestack’s multi-omics data catalog, curation and integrative search product.

Arla Foods Ingredients Group P/S (Arla), a subsidiary of Arla Foods amba, and drug formulation company Zerion ApS (ZERION) have entered into an agreement covering the supply of Arla’s novel and very pure ingredient Lacprodan®BLG that is produced through a patented new technology.

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced sponsorship from the Duchenne Research Fund for an award totaling over $100,000.

— Omidubicel represents a potentially transformative cell therapy treatment option for patients in need of a bone marrow transplant — —Newly presented data support clinical benefit demonstrated by primary and secondary endpoints— —Company anticipates BLA submission in second half of 2021—

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of Andy Hurley as its Chief Commercial Officer.

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced today.